---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-204195"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2022-07-28T23:59:59+00:00"
generated_at: "2026-06-24T07:29:18.898289+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Karyopharm EVP Chief Development Officer Ran Frenkel to depart Aug 15; Stuart Poulton promoted to succeed

## Summary
- Ran Frenkel to cease as EVP, Chief Development Officer effective August 15, 2022.
- Stuart Poulton promoted to EVP, Chief Development Officer effective July 27, 2022.
- Poulton previously SVP, Strategy and Portfolio Management since Feb 2022; 25+ years at AbbVie, Amgen, Eli Lilly.
- Data sciences, clinical pharmacology, data management, medical writing, quality consolidated under Poulton or CMO Reshma Rangwala.
- Company plans separation and consulting agreements with Frenkel.

## SEC filing metadata
- accession: 0001193125-22-204195
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2022-07-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000119312522204195/0001193125-22-204195-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000119312522204195/d324083d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-204195
- JSON: https://secwatch.observer/filing/0001193125-22-204195.json
- Plain text: https://secwatch.observer/filing/0001193125-22-204195.txt

## Key facts
- Executive change
  Stuart Poulton changed role as Executive Vice President, Chief Development Officer at Karyopharm Therapeutics Inc..
  - Action: promoted
  - Role: Executive Vice President, Chief Development Officer
  source text: Stuart Poulton, who has served as the Company’s Senior Vice President, Strategy and Portfolio Management since February 2022, has been promoted to Executive Vice President, Chief Development Officer, effective July 27, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503802/000119312522204195/0001193125-22-204195-index.htm
- Executive change
  Ran Frenkel departed as Executive Vice President, Chief Development Officer at Karyopharm Therapeutics Inc..
  - Action: cease to serve
  - Role: Executive Vice President, Chief Development Officer
  source text: On July 26, 2022, Karyopharm Therapeutics Inc. (the “Company”) and Ran Frenkel agreed that Mr. Frenkel will cease to serve as the Company’s Executive Vice President, Chief Development Officer effective August 15, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503802/000119312522204195/0001193125-22-204195-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.